| First Author | Zhou X | Year | 2025 |
| Journal | Cell Rep Med | Volume | 6 |
| Issue | 3 | Pages | 101975 |
| PubMed ID | 39999838 | Mgi Jnum | J:364153 |
| Mgi Id | MGI:8166071 | Doi | 10.1016/j.xcrm.2025.101975 |
| Citation | Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. Cell Rep Med 6(3):101975 |
| abstractText | The formation of immune synapses (ISs) between cytotoxic T cells and tumor cells is crucial for effective tumor elimination. However, the role of ISs in immune evasion and resistance to immune checkpoint blockades (ICBs) remains unclear. We demonstrate that ICAM-1, a key IS molecule activating LFA-1 signaling in T and natural killer (NK) cells, is often expressed at low levels in cancers. The absence of ICAM-1 leads to significant resistance to T and NK cell-mediated anti-tumor immunity. Using a CRISPR screen, we show that ICAM-1 is epigenetically regulated by the DNA methylation pathway involving UHRF1 and DNMT1. Furthermore, we engineer an antibody-based therapeutic agent, "LFA-1 engager," to enhance T cell-mediated anti-tumor immunity by reconstituting LFA-1 signaling. Treatment with LFA-1 engagers substantially enhances immune-mediated cytotoxicity, potentiates anti-tumor immunity, and synergizes with ICB in mouse models of ICAM-1-deficient tumors. Our data provide promising therapeutic strategies for re-engaging immune stimulatory signals in cancer immunotherapy. |
